Patient-Reported Preferences in Treatments Approved in Neuroendocrine Tumors: A National Survey from the French Group of Endocrine Tumors

#1591

Introduction: Patients with advanced neuroendocrine tumors (NETs) benefit from an increasing number of treatments. The patient’s preference could help physicians to choose among these options

Aim(s): Our patient-reported outcome survey aims to compare the perceived tolerance of treatments approved in NET patients

Materials and methods: Patients with advanced NETs treated by at least 3 different treatments were eligible. Patients evaluated their perceived tolerance from 1 (good) to 5 (poor) for each received treatment. Referent physician confirmed the type and ranking over time of each treatment.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Thomas W

Authors: Plante A, Baudin E, Do Cao C, Hentic O, Dubreuil O,

Keywords: neuroendocrine tumor, toxicity, PRO,